spacer
home > pmps > spring 2017 > open and close
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Open and Close

For packaging to be child-resistant, it must be difficult for a child under the age of four years and four months (52 months) to open or gain access to the contents in a reasonable period – but not challenging for an adult up to 70 years old to use properly. This is the generally accepted definition, and is used in international and European standards as well as the Code of Federal Regulations (CFR) in the US (it is worth noting at this point that child-resistant packaging is not ‘child-proof’).

Child-resistant reclosable packs were first introduced in the UK in the mid- 1970s as an American import and have achieved increasing acceptance in the UK and other EU member states over the past 40 years. In Britain, non-reclosable child-resistant packs were slow to emerge and were only standardised in 2001. As well as being subject to international, European and American standards, the use of child-resistant packs for certain products has been set out in various regulations, including the Human Medicines Regulations 2012 and the globally harmonised system of classification and labelling chemicals, which came into full force in 2015.

Since its introduction, this type of packaging has been improved and made more effective, not only in levels of resistance to opening by children but in its ease-of-use by adults. In addition, increasing and ongoing efforts have been made to create more lightweight packaging across the board.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Stephen Wilkins was appointed Chief Executive Officer of the Child-Safe Packaging Group upon its formation in 1995 and has driven its activities since then. In addition, he is Director of Davies Development and Testing and sits on a number of BSI and ISO committees concerned with developing standards for packaging. Stephen attended the University of Durham Business School, UK, where he obtained a Master’s degree in Business Administration.
spacer
Stephen Wilkins
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Restructure Announcement at Illingworth

As a rapidly growing company, Illingworth Research Group (Illingworth) has reflected on its goals, accomplishments and ambitious future growth plans. This has allowed us to consider opportunities for staff to explore their own growth and development possibilities within a rapidly changing landscape. With that in mind, Illingworth are announcing some significant and exciting changes to our organization. Illingworth remain committed to making patient involvement in clinical trials as stress free as possible and our strengthened management team and launch of our patient concierge service, PatientGO, in combination with global, mobile research nursing will ensure as many patients as possible have the chance to participate in the development of critical drugs, regardless of their geography or socioeconomic class.
More info >>

White Papers

Successfully managing the unique demands of cell therapy supply chains

PCI Pharma Services

Cell therapy professionals joined a specialist webinar by industry experts from PCI Clinical Services and TrakCel, addressing the unique complexity of an autologous therapy supply chain. Hosted by European Pharmaceutical Manufacturer magazine, the webinar was delivered by Rachel Griffiths, Associate Director, Technical Services, PCI Clinincal Services, and Dr. Matthew Lakelin, Vice President, Scientific Affairs and Business Development, TrakCel . Here, we present the white paper from that webinar event.
More info >>

 
Industry Events

INTERPHEX 2020

15-17 July 2020, Javits Center NYC


More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement